At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 38 enrolled
Drug / intervention
Rifaximin +1 moredrug
Likely dose
Rifaximin 550mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Impact of Rifaximin Therapy on Intestinal Byproducts in Chronic Kidney Disease
In Brief
A Phase 4 clinical trial evaluating Rifaximin and Placebo for Chronic Kidney Disease. Completed, enrolled 38 participants across 1 site.
Detailed Summary
The purpose of this study is to determine if Rifaximin decreases serum and urine levels of bacterial byproducts and inflammatory markers in patients with chronic kidney disease and to evaluate changes in the bacterial content of the stool from these individuals.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Kidney Disease
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 2015
Enrollment StartJun 2015
Primary CompletionMar 2019
TodayJul 2026
First PostedJan 21, 2015
Enrollment StartJun 1, 2015
Primary CompletionMar 1, 2019
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 11.4 years ago
Interventions
Rifaximindrug
550mg pills
Placebodrug
Placebo pill